List of works - Joseph Gera

A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity

scientific article published on 08 August 2019

A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets.

scientific article

Conditional astroglial Rictor overexpression induces malignant glioma in mice

scientific article

Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

scientific article published on 06 February 2019

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

scientific article

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.

scientific article published on November 2014

Deadenylation-Dependent and -Independent Decay Pathways for α1-Tubulin mRNA in Chlamydomonas reinhardtii ⬇️

scientific article published on March 1, 1998

Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor ⬇️

scientific article published on March 15, 1991

Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells ⬇️

scientific article published on February 15, 1992

MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells

scientific article

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses

scientific article

Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.

scientific article published on 28 February 2013

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma

scientific article published on 11 May 2016

Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamy

scientific article

Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness

scientific article published on 21 May 2015

Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress

scientific journal article

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

scientific article

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma

scientific article published on 05 January 2020

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.

scientific article

Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.

scientific article published on 6 September 2017

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

scientific article

Targeting cancer with a lupus autoantibody

scientific article published on October 2012

The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and

scientific article

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma ⬇️

scientific article published on May 23, 2011

The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma

scientific article published on 31 August 2019

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

scientific article published on 11 May 2015

mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma

scientific article

mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.

scientific article published on 23 October 2017

List of works by Joseph Gera

A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity

A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets.

Conditional astroglial Rictor overexpression induces malignant glioma in mice

Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.

Deadenylation-Dependent and -Independent Decay Pathways for α1-Tubulin mRNA in Chlamydomonas reinhardtii ⬇️

Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor ⬇️

Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells ⬇️

MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses

Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma

Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamy

Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness

Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.

Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Targeting cancer with a lupus autoantibody

The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma ⬇️

The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma

mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.